CROI (Conference on Retroviruses and Opportunistic Infections)
The Latest

Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.

Researchers Discuss the Lessons of the HIV Vaccine Trial That Terminated Earlier This Year
HVTN 702 may not have proven an effective vaccine, but scientists still learned from the research.

A PrEP Pricing Pickle: Descovy Will Need a Drastic Discount to Be Worthwhile, Study Finds
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

CROI 2020: What to Expect in HIV Science From This Year’s Conference
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.

The Next Frontier of U=U Science
Undetectable equals untransmittable (U=U) has improved HIV prevention and tackled stigma, but there are still a few questions to answer.

Not Surprisingly, PopART Study Showed Community-Based Services Reduce HIV Incidence
"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."

Drug Use May Be Increasing Syphilis Rates Among HIV-Positive Cisgender Women, Studies Show
The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.

CROI 2019: What News to Expect in HIV Science and Policy
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

Retaining Patients in PrEP Care Faces Many Hurdles, Studies Show
Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.